← 返回

In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.

In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.

期刊: International journal of molecular sciences 日期: 2026-07-29 PMID: 42589461 DOI: 10.3390/ijms27156804 浏览: 7
作者: Regev D, Etzion S, Goldbart A, Gopas J
D, R., S, E., A, G., & J, G. (2026). In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.. International journal of molecular sciences. https://doi.org/10.3390/ijms27156804
D R, S E, A G, J G. In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.. International journal of molecular sciences. 2026; doi: 10.3390/ijms27156804
D R, S E, A G, et al. In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.[J]. International journal of molecular sciences. 2026. DOI: 10.3390/ijms27156804.
@article{d2026,
  author = {Regev D and Etzion S and Goldbart A and Gopas J},
  title = {In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.},
  journal = {International journal of molecular sciences},
  year = {2026},
  doi = {10.3390/ijms27156804},
  note = {PMID: 42589461},
}
TY  - JOUR
AU  - Regev D
AU  - Etzion S
AU  - Goldbart A
AU  - Gopas J
TI  - In Vitro Modelling of Obstructive Sleep Apnea by Intermittent Hypoxia of Human Embryonic Stem Cell-Derived Cardiomyocytes: Expression of ERK1/2, ERK5 and Erbin.
T2  - International journal of molecular sciences
PY  - 2026
DO  - 10.3390/ijms27156804
AN  - PMID:42589461
ER  - 

摘要

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive nocturnal airway obstruction and is associated with intermittent hypoxia (IH). The leading cause of death among OSA patients is cardiovascular morbidity, which is greatly enhanced by IH. Despite the existence of standard treatment, cardiovascular morbidity remains unaddressed. Given the central role of IH in OSA-related cardiac damage, the present study aimed to elucidate the mechanisms underlying IH-induced cardiac injury in order to better understand and potentially improve upon current therapeutic approaches. Using human embryonic stem cell-derived cardiomyocytes (hESC-CMs) as a novel in vitro model, IH was successfully induced, and its effects on key signaling pathways were investigated. Following IH exposure, significant activation of ERK1/2, ERK5, and Erbin was demonstrated. Notably, the concurrent increase in both ERK1/2 activation and Erbin expression following IH suggests a more complex regulatory relationship between these molecules than previously appreciated. Furthermore, pathway-specific inhibition of ERK1/2 and ERK5 attenuated the IH-induced decline in beating rate, with significant restoration, following normoxic recovery. This study provides an innovative approach for in vitro investigation of OSA-associated cardiovascular morbidity and supports the search for novel pharmacological agents and molecular targets to improve the diagnosis and treatment of affected patients.

AI 智能解读

相关文献

返回分类: 心血管 查看原文 (DOI)
已选择 0 篇文献